AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06172894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APN401
Description: APN401 is a suspension of viable peripheral blood mononuclear cells (PBMCs) from an individual patient that have been transfected with a small interfering ribonucleic acid (siRNA) to reduce Cbl-b expression. It is administered intravenously in 3-weekly intervals (i.e. every 21 days) for a maximum of 4 treatment cycles.
Study NCT05396963 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Egg white
Description: Intake of egg white
Study NCT05396963 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Whey protein
Description: Intake of whey protein
Study NCT05396963 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Maltodextrin
Description: Intake of maltodextrin
Study NCT05951192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat
Description: Commercially manufactured daprodustat (JESDUVROQ) is provided in tablet strengths of 1, 2, 4, 6 and 8 mg. Tablets will be taken whole and patients will be instructed not to cut, crush, or chew tablets.
Study NCT05882578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oncological physical exercise intervention
Description: An initial physical assestment where clinical history, body composition, functionality, cardiovascular fitness and quality of life will be tested.~Patients will be screened and then divided in diferent groups, depending on both their cardiovascular and physical capacity.~Then they will perform 2 sessions of combined strength and endurance training per week for 16 weeks.~At the end of the training program, the patients will be assesed to evaluate the changes in their cardiovascular fitness, functionality, body composition and quality of life.
Study NCT05326386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HTN and Medication Adherence
Description: Via the Way to Health platform, all patients will receive daily text messages asking about medication adherence for that day and twice weekly text messages asking if participants have measured blood pressure on that day.~Participants are entered into a game. Each week they receive 90 points. If they took their medications or checked their blood pressure the prior day, they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 70 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner. At the start of the intervention, the study team holds a 3-way phone call with the participant and support partner to discuss ways they can help the participant meet their goal. The support partner gets a weekly email with the participant's progress.~Primary care physicians will receive a monthly email noting patients' self-reported adherence and blood pressure.
Study NCT05538416 — intervention group
Intervention type: PROCEDURE
Intervention: Posterior Lumbar Interbody Fusion (PLIF)
Description: Spinal fusion in the lumbar spine by inserting a cage directly into the disc space. This is an observational study in which the standard procedure/care is followed.
Study NCT05882578 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Physical Activities intervention
Description: An initial physical assestment where clinical history, body composition, functionality, cardiovascular fitness and quality of life will be tested Patients will be suggested to mantain active physical activities in their daily life.~At the end of the training program, the patients will be assesed to evaluate the changes in their cardiovascular fitness, functionality, body composition and quality of life.
Study NCT05916352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine Supplement
Description: Caffeine tablet
Study NCT05916352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine Supplement
Description: Caffeine tablet
Study NCT04814264 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Red blood cells
Description: All transfused red blood cells will be obtained from Canadian Blood Services and will be the standard red blood cell products currently provided in Canada.
Study NCT05428709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute Exercise
Description: Participants will be asked to walk or jog on a treadmill for a maximal exercise test.
Study NCT05376319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: 1000 mg per infusion given approximately two weeks apart, on day 1 and on day 15
Study NCT05376319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 1000 mg per infusion given approximately two weeks apart, on day 1 and on day 15
Study NCT05170594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at 15mg/kg IV, every 3 weeks
Study NCT05170594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: The non-platinum chemotherapy regimen will be determined by the investigator.
Study NCT05170594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib will be administered orally continuously at 150mg bid until disease progression and toxicity becomes intolerable
Study NCT04815759 — intervention group
Intervention type: OTHER
Intervention: routine dental restorative procedures
Description: pulp and restorative therapy
Study NCT04857008 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BNT001
Description: BNT001 is a commercially-available, prescription-only, software / medical device in the form of a digital application (digital app) for use on the participant's mobile device which delivers 10-sessions on cognitive behavioral therapy for cancer patients.
Study NCT05665205 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic plus strength group
Description: A 8 week program of aerobic exercise plus strength exercise of upper and lower limbs in the hospital with a supervised trained physiotherapist
Study NCT05665205 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Aerobic group
Description: This group has a 8 weeks program of only aerobic exercise in the hospital with a supervised trained physiotherapist.
Study NCT05379647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QN-019a
Description: Experimental Interventional Therapy
Study NCT05379647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Monoclonal Antibody
Study NCT05379647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamid
Description: Lympho-conditioning Agent
Study NCT05379647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning Agent
Study NCT05379647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP-16
Description: Lympho-conditioning Agent
Study NCT06265298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conjunctival reconstruction
Description: Conjunctival reconstruction using buccal mucosa taken from the patient's mouth. Following the reconstruction operation, an additional biopsy of buccal mucosa will be taken to develop a laboratory protocol for the transdifferentiation of these buccal cells into corneal epithelial stem cells.
Study NCT05598268 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T3011
Description: T3011 will be administered through IV drip
Study NCT04448301 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PointCheck
Description: This is a usability study on PointCheck, a new technology to detect chemotherapy-induced neutropenia
Study NCT06565650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miebo
Description: 100% perfluorohexyloctane
Study NCT06565650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.6% sodium chloride solution
Study NCT05339074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: 60 patients will receive ketamine hydrochloride over 12 weeks, flexible dosed between 0.5 mg/kg to 1.0 mg/kg
Study NCT05486728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHJ002/Vehicle
Description: Topical ophthalmic
Study NCT05486728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHJ002/Vehicle
Description: Topical ophthalmic
Study NCT05838599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: 5% cream applied topically 5 days/week for 6 weeks
Study NCT05838599 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 2 fractions of 4 Gys (total of 8 Gys) starting 1 week after Imiquimoid course over 2 days.
Study NCT06438003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Special Services
Description: Community members will complete data collection at the extension office or community partner location. Extension cooking classes and helping to make raised bed gardens along with other area happenings will be offered to participants throughout the year with check-ins and reminders. Data will be collected from study participants (regardless of the intervention decided) , at two time points, to include survey, dietary recall, and carotenoid scanner.
Study NCT06438003 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Services as Usual
Description: Community members will receive extension services as usual with Data collection on participants at two time points to assess changes in rates of food insecurity, dietary quality, and overall health conditions.
Study NCT05652842 — intervention group
Intervention type: BEHAVIORAL
Intervention: Work-type
Description: Participants are categorized by the type of work hours they must maintain. For example, regular work hours, shift work, and rotational work.
Study NCT05362084 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: lumbar medial branch block
Description: lumbar medial branch block
Study NCT05362084 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lumbar medial branch block
Description: lumbar medial branch block
Study NCT04999969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0171
Description: AZD0171
Study NCT04999969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab
Study NCT04999969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Chemotherapy (Standard-of-Care)
Study NCT04999969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Chemotherapy (Standard-of-Care)
Study NCT05927415 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod IV
Description: Intravenous infusion of efgartigimod
Study NCT04849013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo Capsules containing mannitol looking identical to the other drugs Other: Placebo Capsules containing mannitol looking identical to the other drugs
Study NCT04849013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mescaline 100mg
Description: Drug: 100mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)
Study NCT04849013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mescaline 200mg
Description: Drug: 200mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)
Study NCT04849013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mescaline 400mg
Description: Drug: 400mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)
Study NCT04849013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mescaline 800mg
Description: Drug: 800mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)
Study NCT04849013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mescaline 800mg + Ketanserin 40mg
Description: Drug: 800mg Mescaline per os, single dose~Other: 40mg Ketanserin per os, single dose
Study NCT05856435 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Chicago Parent Program for Foster Care
Description: The Chicago Parent Program for Foster Care FC consists of a 12-session parent training program that focuses on building caregiver-child relationships, behavioral management strategies, managing caregiver stress, and skill maintenance.
Study NCT05920226 — intervention group
Intervention type: DEVICE
Intervention: pacemakers implantation and assessment of cardiac function and cardiac fibrosis
Description: 150 patients will be implanted with pacemakers. In addition to the echocardiography, contrast-enhanced cardiac MRI and peripheral venous blood sampling for myocardial fibrosis markers, the tests described above will be repeated at 1 (V1), 12 (V2), 24 (V3) months after inclusion. Echocardiography and peripheral venous blood sampling for myocardial fibrosis markers detection will be repeated to all patients before pacemakers implantation and after 6,12 and 24 months of observation period. Contrast-enhanced cardiac magnetic resonance imaging (MRI) will be performed before pacemaker implantation and 6 months after surgery.~In addition, pacemakers programming data will be evaluated after 1, 12, 24 months after inclusion in the study (atrioventricular delay, percentage of ventricular stimulation, episodes of high atrial frequency, fibrillation/atrial flutter, ventricular tachycardia).
Study NCT05920226 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: assessment of cardiac function and cardiac fibrosis
Description: The patients who do not require a pacemaker placement will undergo diagnostic testing such as echocardiography, contrast-enhanced cardiac MRI and peripheral venous blood sampling for myocardial fibrosis markers.
Study NCT04651712 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: POC-PCR
Description: The result of the POC-PCR will be presented by the study assistant to the treating physician within four hours upon admission. The treating physician will along with the result receive a recommended action list, developed by microbiologists.
Study NCT05527080 — intervention group
Intervention type: OTHER
Intervention: physiotherapy
Description: Some infants will receive physiotherapy as a part of their clinically indicated care.
Study NCT05527080 — intervention group
Intervention type: DEVICE
Intervention: brace
Description: Some infants in the hip dysplasia group will receive brace and/or cast as a part of their clinically indicated care
Study NCT04490356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Legacy Intervention
Description: The Legacy intervention is a nutrition and exercise protocol delivered using video conference technology. The Legacy protocol incorporates behavioral strategies along with nutrition and exercise to maintain and extend functional benefits of obesity treatment.
Study NCT06342141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 milgrams (Mg)
Description: Load dose
Study NCT06342141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 Mg
Description: Maintenance dose
Study NCT05054881 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sciatic nerve blockade under ultrasound control with a peripheral nerve stimulator
Description: Following the ultrasound visualization of the sciatic nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated.If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed.
Study NCT05054881 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sciatic nerve blockade under ultrasound control without a peripheral nerve stimulator
Description: Under ultrasound visualization guidance, the needle owas positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed.
Study NCT06059859 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Augmented reality robot-assited radical prostatectomy
Description: Robot assisted radical prostatectomy using the Da Vinci surgical robot system (XI model; Intuitive Surgical, Sunnyvale, Calif) and a port device (Alexis; Applied Medical, Rancho Santa Margarita, Calif) system for prostate extraction. Virtual image of the prostate will be overlapped onto the endoscopic view of the Da Vinci surgical robot system using the TilePro system.
Study NCT06059859 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mixed reality intraoperative frozen section analysis
Description: Microsoft Hololens head-mounted display system will be used for inking prostate margins during intraoperative frozen section analysis
Study NCT06059859 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robot-assited radical prostatectomy
Description: Robot assisted radical prostatectomy using the Da Vinci surgical robot system (XI model; Intuitive Surgical, Sunnyvale, Calif) and a port device (Alexis; Applied Medical, Rancho Santa Margarita, Calif) system for prostate extraction.
Study NCT04607096 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent fasting
Description: The intermittent fasting intervention consists of a decreased daily caloric intake of 400 kcal below individual requirements (Harris Benedict Formula) combined with early time restricted fasting according to the schema 16:8. fasting will be performed over 4 weeks.
Study NCT04607096 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control diet
Description: Control group will be advised to reduce daily caloric intake of 400 kcal below individual requirements (Harris Benedict formula)
Study NCT04716322 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Adapted Physical Activity
Description: A 16-week health-adapted physical activity program, individualized from baseline evaluation of participants including the specificities of their pathologies
Study NCT05655585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Release Technique
Description: Participant will be in prone position on a couch with the therapist standing next to the patient. The patient is asked to flex the knee to 90 degree of the involved side. The therapist then applies gentle tension longitudinally to the hamstring muscle along the entire length while the patient actively moves his knee from flexion to extension
Study NCT05655585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Bent Leg Raise
Description: Participant was in supine lying on a high couch with the therapist in standing position lateral to the leg, which is to be stretched. Hip and Knee of the side to be stretched was bent at 90- 90 degree. Investigator places participant's flexed knee over his shoulder such that the popliteal fossa of the knee rest on his shoulder. A distraction (longitudinal traction force along the long axis of femur) was applied at the lower end of femur
Study NCT06236191 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial pulsed current stimulation
Description: A form of transcranial electrical stimulation that delivers unidirectional monophasic rectangular pulses of current.
Study NCT06236191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Melatonin
Study NCT04817852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBCT data of c-shaped canal in mandibular second molar.
Description: Detection of variation in root canal morphology in mandibular second molar by using CBCT.
Study NCT05582954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EsteemUp
Description: EsteemUp is a guided e-health application based on cognitive-behavioural therapy (CBT). It consists of four modules that take approximately 30 to 45 minutes to complete. Each module includes evidence-based psycho-education, reflection questions, interactive exercises, and homework assignments. The content is delivered both textually and visually, including the use of pictures, infographics and videos. Every week trained e-coaches (trained clinical psychology master students) will provide asynchronous written personalized feedback to each participant on the progress of the program and the exercises via the program platform.